2022 World Conference on Lung Cancer (ePosters)-EP08.02-133. Sequential Afatinib to Osimertinib in EGFR-mutant NSCLC: A Prospective Observational Study, Gio-Tag Japan Interim Report

EP08.02-133. Sequential Afatinib to Osimertinib in EGFR-mutant NSCLC: A Prospective Observational Study, Gio-Tag Japan Interim Report

Back to course

Pdf Summary

The Gio-Tag study, a global observational study, found that sequential afatinib and osimertinib therapy can result in prolonged time on treatment for non-small cell lung cancer (NSCLC) patients with EGFR mutation. The study included only 12 Japanese patients out of a total of 204 patients evaluated, highlighting the need for more real-world data (RWD) evaluation in Japan. The interim report of the Gio-Tag Japan study provides information on the starting dose, overall response rate (ORR), and progression-free survival (PFS) of afatinib.<br /><br />The study collected data from medical records of patients who received afatinib as first-line treatment and had T790M-positive cases. The primary endpoint was the TOT of sequential afatinib and osimertinib therapy in these cases. The study is a prospective, multicenter observational study and was registered with the University Hospital Medical Information Network (UMIN) and approved by the institutional review board (IRB).<br /><br />The interim report shows that the starting dose of afatinib was reduced in approximately half of the patients, mainly due to elderly age and toxicity concerns. Subgroup analysis demonstrated a median PFS of 18.4 months in patients with Del-19 mutation and 15.8 months in patients with L858R mutation. The Japanese RWD of afatinib showed comparable ORR and DCR (disease control rate) and a potentially more favorable PFS compared to previous trials.<br /><br />Overall, the interim report suggests that sequential afatinib and osimertinib therapy may be an effective treatment option for NSCLC patients with EGFR mutation. However, further evaluation of real-world data in Japan is needed to fully understand the benefits and efficacy of this therapy in the Japanese population.

Asset Subtitle

Ryo Morita

Meta Tag

Speaker Ryo Morita

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

Gio-Tag study

afatinib and osimertinib therapy

NSCLC

EGFR mutation

real-world data

Gio-Tag Japan study

starting dose

progression-free survival

T790M-positive cases

Japanese RWD